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The great properties of human mesenchymal stromal cells (hMSCs) make these cells an important tool in regenerative medicine.
Because of the limitations of hMSCs derived from the bone marrow during isolation and expansion, hMSCs derived from the
umbilical cord stroma are a great alternative to overcome these issues. For a large expansion of these cells, we performed a process
transfer from static culture to a dynamic system. For this reason, a microcarrier selection out of five microcarrier types was made
to achieve a suitable growth surface for the cells.The growth characteristics andmetabolite consumption and production were used
to compare the cells growth in 12-well plate and spinner flask. The goal to determine relevant process parameters to transfer the
expansion process into a stirred tank bioreactor was achieved.
1. Introduction
Mesenchymal stromal cells (MSCs) play an important role in
regenerative medicine, for cell therapy or tissue engineering
[1–4]. This importance is based on properties of these
cells. MSCs have the capacity to differentiate to osteoblasts,
adipocytes, and chondrocytes, which classifies MSCs as mul-
tipotent stromal cells [5–8].MSCsmaymodulate the immune
system [8–14] and enable tissue repair [1] by secretion of
growth factors, cytokines, and other signaling molecules
into the medium [1, 15]. The immune properties of MSCs
give these cells an important role to treat immunological
disorders, such as graft-versus-host disease [9].
MSCs are found in other tissues beside themarrow cavity;
for example, they can be found in blood or adipose tissue [8],
dermis, muscle, dental pulp, umbilical cord blood, placenta,
perivascular areas, amniotic fluid, and tissues surrounding
the umbilical cord vessels, calledWharton’s jelly [8, 9, 16].The
advantage of isolation ofMSCs from the umbilical cord is that
collection is safe and painless tomother and child, in contrast
to the invasive and painful extraction of MSCs from the bone
marrow.
While there are advantages to the choice of human
umbilical cordmesenchymal stromal cells (hUCMSCs) as an
MSC source, there are distinct challenges to using this source,
which include the lack of standardized method for isolating,
expanding, and validating hUC MSCs. These important
limitations are not addressed here but are addressed in our
companion paper [17].
The International Society for Cellular Therapy (ISCT)
provides three minimal criteria to identify MSCs [18]. First,
MSCs must be tissue culture plastic-adherent when main-
tained in standard culture conditions. Second, they express
specific surface antigens CD105, CD73, and CD90 and they
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do not highly express markers of the hematopoietic lineage
such as CD45, CD34, CD14, CD11b, CD79𝛼, CD19, or HLA
class II [18]. The third criterion is that MSCs must be capable
of differentiating to osteoblasts, adipocytes, and chondro-
cytes in vitro [18]. Our group at the Kansas State University
in Manhattan, Kansas [19–21], and two other laboratories,
Dr. Davies’ lab at the University of Toronto [22] and Dr.
Fu at the National Yang-Ming University, Taipei [23, 24],
have shown the isolation and characterization of hUC MSCs
fromWharton’s jelly and classified these cells as MSCs based
upon their ability to produce bone, cartilage, and fat in
vitro [8]. In addition to their differentiation capacity, hUC
MSCs may differentiate to neuron-like cells [19, 25–28] and
spontaneously beating cardiomyocytes [29]. Compared to
hUCMSCs, in vitro expansion of adult bone-marrow-derived
MSCs (BM MSCs) is slower [9]. When comparing the risks
and safety margin, and the low cost and inexhaustible supply,
hUCMSCs are a good alternative to BMMSCs tomanage the
graft-versus-host disease during the cell transplantation [9].
For a clinical use, large numbers of hUC MSCs (2-3
million MSCs⋅kg−1) and perhaps repeated doses are required
[30–33]. The challenge of manufacturing the required
amounts of cells requires a microcarrier-based stirred tank
bioreactor process. The stirred tank bioreactor is a well-
known, monitored, and controlled bioreactor system which
enables a robust and reproducible culture process and a safe
and reliable cell product according to Good Manufacturing
Practice (GMP) and Good Clinical Practice (GCP) require-
ments. Since hUCMSCs are grown as adherent cells, suitable
microcarriers must be chosen to provide an adequate growth
surface.
Several research groups have shown MSC expansion in
a dynamic bioreactor system. Chen et al. [34] show an
optimized expansion of human fetal-derived MSCs in 2 L
stirred tank cultures using Cytodex 3 microcarriers. They
achieved a cell concentration of 1 × 106 cells⋅mL−1 with con-
fluent cell concentration of 4.7 × 104 cells⋅cm−2. Dos Santos
et al. [35] evaluated the expansion of BM MSCs and adipose
tissue-derived MSCs (ASC). They developed a xenogeneic-
free protocol for a 1 L-scale controlled stirred tank bioreactor
with nonporous plastic microcarrier and analyzed different
air concentrations in the medium and different medium
exchanges and feeding strategies. They reached a final cell
yield of (1.1 ± 0.1) × 105 cells⋅mL−1 for the ASC MSCs and
(4.5 ± 0.2) × 104 cells⋅mL−1 for the BM MSCs. Cierpka et
al. [36] reported the expansion of human MSCs derived
from bone marrow in a disposable stirred tank bioreactor
system according to GMP and PAT (Process Analytical
Technology) requirements. The evaluated growth rates were
0.45 to 0.53 d−1; the final cell density was 5 × 104 cells⋅cm−2
with a total cell number of 2.7× 105 cells⋅mL−1.The expansion
was performed as a 2.4 L fed-batch process with a 6-times
higher expansion factor compared to the batch cultiva-
tion. The growth surface was a collagen-coated microcarrier
(SoloHill) and the culture was started with a low glucose
DMEMmediumand fedwith a high glucoseDMEMmedium
and fresh microcarriers. This expansion strategy, called
bead-to-bead transfer, allows the low inoculation density
of 800 cells⋅cm−2. The bead-to-bead transfer describes the
migration of the cells from one microcarrier to another. It
is assumed that during cell division the cells detach from
one microcarrier and attach onto another microcarrier. The
advantage of a bead-to-bead transfer is the prevention of large
precultures.
Based upon this previous work, we considered a micro-
carrier-based process for the expansion of hUC MSCs in
a high surface-to-volume ratio. Our goal was a robust and
reproducible process according to GMP and GCP. To achieve
this goal, this study focused on the characterization of the
cell growth and metabolism of hUC MSCs and the process
transfer from static culturing to a dynamic system. A small-
scale spinner flask culture was used to identify the culture
conditions for the expansion in the bioreactor. The crucial
culture conditionswe evaluatedwere the inoculation strategy,
seeding density, stirrer speed, microcarrier type, and batch
or fed-batch cultivation. We strived for a cultivation strategy
with a high hUCMSCharvest yieldwhich achieved all quality
control criteria of these cells.
2. Materials and Methods
2.1. Umbilical Cord and Cell Isolation. Five human umbilical
cords were used for this work. The cords were discarded
tissues from apparently healthy, anonymous donors. The
work with human tissues was reviewed by the Kansas State
University Institutional Human Subjects Review Board and
deemed to be not human subjects research (IRB review
#5189). The MSCs were isolated from the umbilical cords
using amethod recently developed at Kansas State University
[17]. For this study, we used cells at passage 3.
2.2. Culture Medium. The culture medium for hUC MSCs
was based on DMEM low glucose (LG) medium (Gibco®
by Thermo Fisher Scientific, Cat. number 11885-084) with
addition of 10% pooled human platelet lysate (hPL, pooled
from more than 25 expired units, obtained from Kansas
University Medical Center, Dr. Lowell Tilzer, director), 1%
GlutaMAXTM (Gibco, Cat. number 35050-061), 1% Antibiotic-
Antimycotic (Gibco, Cat. number 15240-062), and 0.4%
Heparin (Kansas State University Veterinary Hospital Phar-
macy, 1000USPU⋅mL−1). All components were combined
and sterile-filtered (0.22𝜇m, Corning®, Cat. number 431098).
The high glucose medium was made by the same procedure,
but the DMEM LG medium is replaced by DMEM high
glucose medium (Gibco, Cat. number 11995-065).
2.3. Growth Kinetic under Static Culture Conditions. The
growth kinetic of five cell populations from different cords
(two male donors, three female donors) in 2D was investi-
gated in a 12-well plate (CytoOne, USA Scientific, Item num-
ber CC7682-7512) to determine the growth parameter and as
a comparison to the cell growth in the dynamic system. The
cells (passage 3) were seeded at a density of 8000 cells⋅cm−2
and a working volume of 1mL DMEM LG medium. The
cells were cultured for 7 days and harvested. To harvest,
the medium of three wells was aspirated, washed once with
1mL Dulbecco’s phosphate buffered saline (DPBS), and lifted
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Table 1: Microcarrier specification for Animal Product-Free Starter Kit by SoloHill, Pall Corporation.
Microcarrier
type Description
Relative density
(g⋅cm−3) Diameter (𝜇m)
Surface per
gram (cm2⋅g−1) Surface charge
Hillex II Modifiedpolystyrene 1.090–1.150 160–200 515 X
Pronectin F
Cross-linked
polystyrene
coated with
recombinant
RGD-
containing
protein
1.022–1.030 125–212 360 X
Plastic Cross-linkedpolystyrene 1.022–1.031 125–213 360
Plastic Plus
Cross-linked
polystyrene,
cationic charge
1.022–1.032 125–214 360 X
Glass
Cross-linked
polystyrene
coated with high
silica glass
1.022–1.033 125–215 360
from the substrate with 0.05% trypsin-EDTA (Gibco, Cat.
number 25200-056). The cell number, cell viability, and cell
size were determined with the Cellometer Auto 2000 Cell
Viability Counter using ViaStain AOPI staining kit (both
from Nexcelom Bioscience, Waltham, MA).
2.4. Microcarrier Selection. For the expansion of hUC MSCs
on microcarriers, five different microcarrier types (Animal
Product-Free Starter Kit, SoloHill® by Pall Corporation) were
compared (threefold determination, 𝑛 = 3) to achieve the
best growth and attachment conditions for the hUC MSCs.
The starter kit contains Hillex® II, Plastic Plus, Plastic, Pro-
nectin F-coated, and Glass-coated microcarriers (Table 1).
In addition to these five microcarrier types, the effect of
hydrogen chloride treatment on the Glass-coated microcar-
riers was tested. The Glass-coated microcarriers (100 g) were
incubated in a bottle with 100mL 1M HCl overnight (16 h)
at room temperature. After the incubation, the microcarriers
were washed and dried. For each microcarrier type, 1 g
microcarriers was autoclaved with 3mL DPBS at 121∘C and
100 kPa over pressure for 20min. The microcarrier selection
was performed in an ultralow attachment 6-well plate (Corn-
ing Costar®, Sigma-Aldrich®, Cat. number CLS3471-24EA)
with a seeding density of 8000 cells⋅cm−2, 1.5mL DMEM
LG medium, and 25 g⋅L−1 microcarriers over 3 days for
each microcarrier type. Every day, the cells of three wells
were harvested. 1mL was taken into a reagent cup, the
microcarriers settled to the bottom, and we removed the
supernatant, added 400 𝜇L of trypsin-EDTA (0.05%), and
incubated the sample for 5min under swirled conditions at
37∘C and 5% CO2. The reaction was stopped with 800𝜇L of
hPL containing fresh and prewarmed culture medium and
the cells were separated from the microcarrier through a cell
strainer (Miltenyi Biotec, MACS SmartStrainers, 30𝜇m, Cat.
number 12-565-271). The cell strainer was rinsed three times
with 1mL DPBS. After centrifugation (5min, 200×g), the
supernatant was discarded and the cells were resuspended
in fresh and prewarmed culture medium. Cell number, cell
viability, and cell size were determined with the Cellometer
Auto 2000 Cell Viability Counter.
2.5. Spinner Cultivation. The hUC MSCs were cultured in
spinner flasks (Bellco, IOBW/MCFLASK, 100mL,Cat. num-
ber 1965-61001) with 100mL working volume and 25 g⋅L−1
microcarriers. The cells were seeded at 8000 cells⋅cm−2 and
DMEM LG medium (see Section 2.2). For the first 24 h, the
cells were cultured with 25 rpm stirrer speed to facilitate
the attachment of the cells. After 24 h, the stirrer speed was
increased to 40 rpm and every second day, the speed was
increased by about 10 rpm to avoid microcarrier agglomer-
ation. A 50% medium exchange was performed when the
glucose concentration in the medium dropped to 0.2 g⋅L−1.
The medium was exchanged with fresh and prewarmed
culture medium with a glucose concentration of 2 g⋅L−1 to
achieve an end concentration of 1.2 g⋅L−1 in the spinner flask.
Every day a sample was taken from the spinner flask to
determine cell number, cell viability, cell size, andmetabolites
(see Section 2.9). After 6–8 days of culture, the entire spinner
was harvested. To harvest, the stirrer speed was set to
0 rpm to let the microcarriers settle down and as much as
possible (80–90mL) of the culturemediumwas removed.The
microcarriers were washed two times with 20mL prewarmed
DPBS and incubated with 15mL prewarmed 0.05% trypsin
for 10 minutes at 37∘C and 5% CO2 to detach the cells
from the microcarriers. The trypsin reaction was stopped
with 40mL fresh and prewarmed culture medium. The cells
were separated from the microcarriers through a cell strainer
(30 𝜇m) and rinsed with DPBS. After centrifugation (5min,
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200×g), the supernatant was discarded and the cells were
resuspended in fresh and prewarmed medium to determine
cell number, cell viability, and cell size.
2.6. Differentiation Analysis. After spinner harvest, hUC
MSCs were seeded in a 12-well plate (CytoOne, USA Scien-
tific, Item number CC7682-7512) to confirm the differentia-
tion capacity. This was performed according to the protocols
of the StemPro® differentiation kits for adipogenesis, chon-
drogenesis, and osteogenesis by Thermo Fisher Scientific.
2.7. Cell Count and Maximal Growth Rate. Cell count, cell
viability, and cell size were determined with the Cellometer
Auto 2000 Cell Viability Counter using the ViaStain AOPI
staining kit (both from Nexcelom Bioscience, Waltham, MA,
USA). The exponential growth phase of the cells was esti-
mated from a line created by plotting the natural logarithm
of the cell number against the culture time. The slope of
this linear curve is determined by linear regression analysis
(GraphPad Prism, Version 5.01, GraphPad Software Inc.),
which represents the maximal growth rate.
2.8. Microscopic Analysis of Cell Growth. The qualitative
analysis was done by staining the cell nuclei on the micro-
carriers with SYBRGreen I (10,000x concentrate in DMSO,
Cat. number S-7563).The stock solution of SYBRGreen I was
diluted 1 : 10000 with DPBS for staining. For detection with a
fluorescentmicroscope (EVOS® FLAuto Imaging System), an
absorption wavelength of 497 nm and emission wavelength
of 520 nm were used. The distribution and occupancy of
microcarrier with cells were determined by counting the
number of microcarriers with and without cells.
2.9. Metabolite Analysis. Themetabolites glucose, glutamine,
lactate, and ammonium were measured in the cell cul-
ture medium. The metabolite concentrations were measured
using a BioProfile® 400 (Nova Biomedical, Waltham, MA).
The consumption and production rates were determined
by plotting the metabolite concentration over the culture
time and calculation of the slope for linear consumption
or production using linear regression analysis. The ratio
of produced lactate to the consumed glucose called lactate
yield and the ratio of produced ammonium to consumed
glutamine (ammonium yield) for the static and dynamic
cultivation were determined between 24 and 48 h. These
yields serve for classification of the metabolism pathway.
2.10. FlowCytometry. Theflow cytometrymethods employed
here are identical to those described in our adjacent paper
[17] to permit comparisons between the results of MSCs
expanded in static culture and those expanded in dynamic
culture. Briefly, the BD StemflowTM Human MSC Analysis
Kit (BD Biosciences, Cat. number 562245) was used for
positive andnegative surfacemarker staining.Using theman-
ufacturer’s protocol, hUC MSC samples were stained with
four fluorochromes together including positive and negative
staining cocktails. The positive marker cocktail stained for
CD90, CD105, and CD73 (defined as >97% positively stained
cells).The negative cocktail (all antibodies were stained using
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Figure 1: Growth kinetic of hUC MSCs from two different donors
(HUC#255, female: white squares;HUC#256,male: black circles) in
static 12-well culture plate in 1mL DMEM LGmediumwith seeding
density of 8000 cells⋅cm−2.
a single fluorochrome, PE) stained for CD34, CD45, CD11b,
CD19, and HLA-DR (defined as <2% positively stained cells).
A CD44 labeled PE antibody was used as positive control for
the negative cocktail to set the compensation and gating of
the negative cocktail. For additional methodological details,
see [17].
2.11. Colony Forming Unit-Fibroblast Assay. The CFU-F
methods employed here are identical to those described in
our adjacent paper [17] to permit comparisons between the
results of hUC MSCs expanded in static culture and those
expanded in dynamic culture. Briefly, hUCMSCs were plated
at 5 or 10 cells⋅cm−2 in duplicates in 6-well CytoOne tissue
culture plates in DMEM LG. Cells were expanded 4 days in
culture, prior to fixation and methylene blue staining. For
additional methodological details, see [17].
2.12. Karyotype Analysis. Following expansion of hUCMSCs
in dynamic culture, the cells were cryopreserved to mimic
how the cells might be banked prior to therapeutic appli-
cation. The cells were subsequently thawed and plated at 1–
1.5 × 104 cells⋅cm−2 in DMEM LG, as described in [17]. Once
attachment and expansion of the hUCMSCswere confirmed,
the tissue culture flasks were submitted to Cell Line Genetics
for karyotype analysis (Cell Line Genetics, Madison, WI).
3. Results
3.1. hUCMSCGrowthKinetic under Static Culture Conditions.
The growth kinetic in 12-well plates was done to identify
differences in the cell growth and metabolism of hUC MSCs
from five donors (Table 2) and serves as comparison for the
dynamic system. Figure 1 shows representative cell growth
data of hUCMSCs from one male and one female donor. All
cells were in passage number 3 for better comparability and
to avoid any influence of senescence. No significant difference
was observed between the cells from female or male donors.
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Table 2: Maximal growth rate, minimum doubling time, and fold expansion of hUC MSCs from five donors, after 7 days in culture in 1mL
DMEM LG medium in a 12-well plate at a seeding density of 8000 cells⋅cm−2 (𝑛 = 3).
HUC # Gender Max. growth rate 𝜇max (h
−1) Min. doubling time 𝑡𝐷 (h) Fold expansion
255 Female 0.045 ± 0.002 15.4 ± 0.6 12.7
260 Female 0.049 ± 0.002 18.1 ± 1.3 11.0
262 Female 0.037 ± 0.004 17.3 ± 1.7 10.9
256 Male 0.038 ± 0.003 14.2 ± 0.5 11.1
257 Male 0.040 ± 0.004 18.8 ± 2.1 11.2
Average 0.042 16.8 11.4
Standard deviation 0.005 1.9 0.7
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Figure 2: Metabolite profile of hUCMSCs from two different donors (HUC #255, female: squares, HUC #256, male: circles) in static 12-well
culture plate in 1mLDMEMLGmediumwith seeding density of 8000 cells⋅cm−2. (a)Grey full—glucose, white—lactate; (b) black—glutamine,
grey empty—ammonium; dotted line: glutamine thermal decay.
The exponential growth phase for all five cell types was
observed between 20 and 100 h of culture time. The highest
cell concentration at the end of the exponential growth phase
reached values from 1.3 × 105 to 2.1× 105 cells⋅cm−2.Themean
value for the maximal growth rate 𝜇max was 0.042 ± 0.005 h
−1
with a resulting doubling time of 16.8±1.9 h and a mean fold
expansion of 11.4 ± 0.7 after 7 days.
The glucose-lactate (a) and glutamine-ammonium (b)
profiles of hUC MSCs from a female and a male donor are
shown in Figure 2. After 3 days the concentration of glucose
in the medium was under the detection limit of 1.1mmol⋅L−1
and the lactate concentration reached a constant level of
4.5mmol⋅L−1 after 4 days. The glucose-lactate profile in rela-
tion to the cell growth (Figure 1) determined the glucose as
limiting substrate for the hUC MSC proliferation. We deter-
mined for hUCMSCs from a female donor 𝑌Lac/Glc of 2.6 and
for a male donor of 2.1 (see Supplemental Table 1 in the Sup-
plementary Material available online at http://dx.doi.org/10
.1155/2016/4834616). The consumption of glutamine was not
limited and is connected with a constant production of
ammonium. The ammonium yield 𝑌NH
4
/Gln of hUC MSCs
from a female donor was 0.8 and from a male donor 0.5. A
difference in the metabolism of hUC MSCs from male and
female donors was not identified.
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Figure 3: Occupancy and confluency of five different microcarriers
after 72 h culture time in ultralow attachment 6-well plates with
0.0375 g of microcarriers in 1mL DMEM LG medium at a seeding
density of 8000 cells⋅cm−2. Bars represent one standard deviation of
threefold determination.
3.2. Microcarrier Selection. Themicrocarriers play an impor-
tant role for the expansion of adherent cells. For this reason,
a microcarrier selection between five microcarrier types
was done (Figure 3). The highest confluency and occupancy
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Figure 4: SYBRGreen stained hUC MSCs on HCl-treated Glass-coated microcarriers (a) and Plastic Plus microcarriers (b) after 3 days of
culture in 1mL DMEMmedium in an ultralow attachment well plate at a seeding density of 8000 cells⋅cm−2 (scale bar = 1000 𝜇m).
were the two crucial criteria for the selection of a suitable
microcarrier type. The Pronectin F, Plastic, and Plastic Plus
microcarriers showed a similar occupancy between 73 and
75%. The obtained cell number from the Pronectin F and
Plastic was lower than that from the Plastic Plus microcarri-
ers.Glass-coatedmicrocarrierswere investigated as untreated
and pretreated with HCl. The pretreatment had a positive
effect, which was visible in the higher final cell number.
However, both Glass-coatedmicrocarrier types showed a low
microcarrier occupancy of around 50% (Figure 4). In consid-
eration of the confluence and the occupancy, the Plastic Plus
microcarriers were the best choice for the expansion of hUC
MSCs.
3.3. hUC MSC Expansion Using Dynamic Spinner Cultiva-
tion. Spinner flasks are a useful instrument for small-scale
investigation of dynamic cell expansion. Inoculationmethods
with different resting times up to 4 h and occasionally
briefly agitations were tested. There was no increase in cell
growth or cell distribution based upon five independent tests
(data not shown). We observed that inoculation strategies
using agitation-rest-cycles led to an unwanted microcarrier
agglomeration.Thereforewe decided for an inoculation strat-
egy under low (25 rpm) but continuous stirring. A seeding
density of 8000 cells⋅cm−2 was found as suitable to avoid large
precultures for inoculation and to prevent long culture times.
To prevent microcarrier agglomeration with increasing cell
number, the stirrer speedwas increased every second day.The
Plastic Plus andHCl-treated Glass-coatedmicrocarriers were
tested in nine spinner flasks trials. A nonhomogeneous cell
distribution on the HCl-treated Glass-coated microcarriers
was observed in the spinner flasks. Also the cell yield for
HCl-treated Glass-coated microcarriers was lower compared
to the Plastic Plus microcarriers (data not shown). We
observed no difference in the growth between cells frommale
and female donors on Plastic Plus microcarriers (Table 3,
Figure 5). In comparison to the static culture, the deter-
mined growth rates from the spinner flasks were comparable.
The hUC MSCs could be efficiently detached with trypsin.
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Figure 5: Growth kinetic of hUC MSCs on Plastic Plus microcar-
riers in spinner flasks in 100mL DMEM LG medium with seeding
density of 8000 cells⋅cm−2 (HUC #255, female: white squares; HUC
#256, male: black circles).
An average cell yield of 4.2 × 107 ± 1.4 × 107 cells from an
entire 100mL spinner is related to a desired cell confluence of
about 4.6 × 104 cells⋅cm−2. This high efficiency of harvesting
hUC MSCs was confirmed by observing bare microcarriers
after SYBRGreen staining of the microcarriers following cell
harvest.
With glucose identified as the limiting substrate, a 50%
medium exchange was done before the glucose concentra-
tion dropped under 1.1mmol⋅L−1. Figure 6 shows a repre-
sentative metabolite profile of hUC MSCs from a female
donor in a spinner flask culture. The medium was exchanged
after 3 and 5 days to achieve a desired glucose concen-
tration of 5.5mmol⋅L−1. We determined 𝑌Lac/Glc of 1.8 and
𝑌NH
4
/Gln of 1.3 between 24 and 48 h expansion time. The
ground metabolism of hUC MSCs in spinner flasks cultures
showed no difference between cells from a male and a female
donor.
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Table 3: Growth characteristics for hUC MSCs on Plastic Plus microcarriers in spinner flasks with 100mL DMEM LG culture medium at a
seeding density of 8000 cells⋅cm−2.
Gender Culture time(d)
Max. growth
rate
𝜇max (h
−1)
Min.
doubling
time 𝑡𝐷 (h)
Fold
expansion
Highest
occupancy
(%)
Harvested
cell yield
Male 7 0.046 ± 0.006 14.9 ± 2.2 16.4 81 2.6 × 107
Female 6 0.032 ± 0.003 21.6 ± 2.5 13.8 93 5.3 × 107
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Figure 6: Metabolite profile of hUC MSCs from a female donor (HUC #255) in a dynamic spinner culture with 25 g⋅L−1, 100mL DMEM
LGmedium, and a seeding density of 8000 cells⋅cm−2. (a) Grey full—glucose, white empty—lactate; (b) black full—glutamine, grey empty—
ammonium.
3.4. Bead-to-Bead Transfer. In our study, the bead-to-bead
transfer was carried out with a feed of fresh medium and
microcarriers after the first microcarriers were confluent.
The working volume and microcarrier mass were doubled.
The cells were cultured up to 10 days and a 50% medium
exchange was performed, when the glucose concentration
in the medium dropped under 1.1mmol⋅L−1. As criterion
for the bead-to-bead transfer, the cell distribution on the
microcarriers was analyzed. After 2 to 3 days a slight increase
of the occupancy to a constant level of about 60–70% was
obtained. In contrast to the rapid rise of the occupancy over
80% after inoculation, the cells did not appear to migrate
to fresh microcarriers. At the end of the culture period,
the microcarriers were either fully confluent with cells or
completely devoid of cells (blank) (Figure 7).
3.5. Quality Control of the hUCMSCs. After the harvest of the
spinner flaks, the cells were seeded in 12-well plates to prove
their ability to differentiate to adipocytes, chondrocytes, and
osteoblasts.The dynamic expanded hUCMSCs were positive
for lipid vesicle-forming adipocytes (Figure 8(a)), for calcium
deposit-producing osteoblasts (Figure 8(b)), and nodule-
forming chondrocytes (Figure 8(c)). Further, it was proven
that the growth characteristics did not change after a spinner
cultivation.Wedetermined no change in the cell growth and a
high cell viability over 90%. Flow cytometry analysis revealed
that the 3D cultured hUC MSCs were positively stained for
surface markers of MSCs and were negative for markers
Figure 7: SYBRGreen stained hUCMSCs on Plastic Plus microcar-
riers after 9 days of culture in 200mL DMEMmedium in a spinner
culture at a seeding density of 8000 cells⋅cm−2. The spinner culture
was started with 100mL working volume and 2.5 g microcarriers.
After 4 days a feed of 100mL fresh medium and 2.5 g fresh
microcarriers was performed to investigate a bead-to-bead transfer.
The microcarriers are either totally confluent with cells or blank
(scale bar = 1000 𝜇m).
of the hematopoietic lineage (see Supplemental Figure 1).
CFU-F analysis revealed that dynamically cultured MSCs
had colony forming efficiency (CFE, defined as the number
of MSCs plated divided by the number of colony forming
unit-fibroblasts) of between 4.5 and 2.5 (see Supplemental
Figure 2). Finally, after reviving hUC MSCs that had been
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(c)
Figure 8: Differentiated hUC MSCs. (a) Adipocytes stained with Oil Red after 21 days (scale bar = 200 𝜇m); (b) osteocytes stained with
Alizarin Red; and (c) chondrocytes stained with Safranin after 22 days (scale bar = 400 𝜇m).
previously expanded in dynamic culture, we found that 94%
of the cells were viable at thaw.These cells were plated in static
culture in 10% HPL enriched DMEM and they expanded
robustly. The hUC MSCs were sent for karyotype analysis at
passage 5, and the karyotype was normal (see Supplemental
Figure 3). These results indicate that dynamically produced
hUCMSCs meet ISCT MSC minimal definition.
4. Discussion
The goal was to investigate variables associated with the
manufacture of hUCMSCs in a xeno-free, scalable, dynamic
culture system. Three novel observations were made. First,
after testing five different microcarriers with differing topog-
raphy and surface chemistry, we found that Plastic Plus
microcarriers were optimal for hUCMSC expansion. Second,
after measuring medium metabolites during expansion, we
found that glucose concentration was the critical variable for
maintaining exponential MSC expansion. Third, by observ-
ing microcarrier occupancy, we determined that bead-to-
bead transfer of MSCs does not occur to a significant degree.
This is critical for designing scalable expansion end points.
Using the International Society of Cellular Therapy min-
imal definition, the hUC MSCs grown in static culture and
in the xeno-free, dynamic cultivation met the minimal MSC
definition [18]; this observation is in agreement with previous
work of microcarrier-based expansion of MSCs [1, 2, 34–36]
or more specifically hUC MSC [37]. Moreover, the colony
forming efficiency of dynamically cultured hUC MSCs is
comparable to that found in static culture [17]. Finally, a nor-
mal karyotype was found of hUC MSCs after microcarrier-
based dynamic expansion, cryobanking, and expansion in
static culture. These findings provide a basis for more highly
refined microcarrier-based bioreactor experiments, scale-
up, and validation studies. These results, together with our
optimized hUC MSC isolation and xeno-free expansion
work described in our adjacent paper [17], address critical
information gap clinical manufacturing needs.
4.1. Comparison of hUC MSCs Expanded in Static and
Dynamic Cultivation. In comparison to BMMSC the prolif-
eration rate of hUC MSCs is higher, which results in lower
doubling times [9, 38]. The determined max. growth rate
of 0.042 ± 0.005 h−1 (𝑡𝐷 = 16.8 ± 1.9 h) is ∼2-fold higher
compared to the reported growth rates in the BM MSC lit-
erature. Majore et al. [39] determined a population doubling
time of 27.5 ± 0.2 h for BM MSCs, which corresponds to a
max. growth rate of 0.025 h−1, and Schop et al. [2] reported
a growth rate of 0.020 ± 0.004 h−1 (𝑡𝐷 = 35.5 ± 6.00 h)
for BM MSCs. The higher proliferation rate of hUC MSCs
could be one explanation for the difference in the growth
rates. Elseberg et al. [1] reported the influence of the glucose
concentration in the medium on the cell growth. They used
an immortalized cell line hMSC-TERT and reported a max.
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growth rate of 0.039 h−1 for the cells in low glucose medium
(EMEM, 1 g⋅L−1 glucose) and a max. growth rate of 0.03 h−1
for the cells in high glucose medium (DMEM, 4.5 g⋅L−1
glucose). This shows the influence of the medium and the
components on the MSC growth. In regard to the fact that
every research groupmay use different medium formulations
it is difficult to compare the cell growth between different
laboratories. For this reasonwe performed the growth kinetic
under static culture conditions to obtain our standard and as
comparison for the dynamic system.
The challenge of the process transfer from static to
dynamic system is the difference of the growth surfaces and
the connected process of cell adhesion (static flat bottom
to suspended round microcarrier). The higher cell density
with sufficient nutrient supply and the potential harmful
effect of shear forces created by stirring or aeration both may
impact the proliferation of sensitive cells.The growth rate can
be used as criterion to compare the different systems. The
max. growth rate of 0.038 ± 0.008 h−1 in the spinner flask
is comparable to the max. growth rate of 0.042 ± 0.005 h−1
from the 12-well plate and both systems show similar growth
kinetics (Figures 1 and 5). Additionally, in both systems, no
influence of the gender from the donor is observed. The final
cell confluency of 5.9 × 104 cells⋅cm−2 for the cultivation of
the cells from a female donor is comparable with the reported
concentrations from Chen et al. [34] and Cierpka et al. [36].
Glucose is the primary source for mammalian cells to
generate ATP by oxidative phosphorylation or by anaerobic
glycolysis [2]. 𝑌Lac/Glc indicates which metabolism pathway
the cells prefer to use to produce energy [2, 40–42]. For
the hUC MSCs in static culture we obtained 𝑌Lac/Glc of
2.6 (female) and 2.1 (male) and for the dynamic system
𝑌Lac/Glc of 1.8 (female and male). Schop et al. [2] declared
that 𝑌Lac/Glc of 2 indicates that the cells use the inefficient
glycolytic pathway instead of the oxidative phosphorylation
to generate energy. The decrease of 𝑌Lac/Glc from static
to dynamic hUC MSC expansion could be explained by
changing the cellularmetabolism from the glycolytic pathway
to the oxidative phosphorylation by higher oxygen transfer in
the spinner flask.The agitation in the spinner flask provides a
homogenous distribution of substrates like glucose or oxygen
in the culture medium, while the mass transfer in the static
culture is driven by diffusion resulting in nutrient gradients.
Glutamine is the second main substrate for mammalian
cell cultures and gets metabolically deaminated to glutamate
[2]. We evaluated for the hUCMSCs 𝑌NH
4
/Gln of 0.8 (female)
and 𝑌NH
4
/Gln of 0.5 (male) in the 12-well plates and 𝑌NH
4
/Gln
of 1.3 (female) and 0.7 (male) for the dynamic culture.
Schop et al. [2] gave 𝑌NH
4
/Gln of 1.6, but they provided
reasons for not using the glutamine consumption and NH3
production for characterization: glutamine in the medium
decays spontaneously and NH3 gets formed spontaneously.
Assuming about ±10% glutamine decomposition per day
[2, 43], Schop et al. calculated a glutamine consumption
close to zero. Here we used 2mmol GlutaMAX (glutamine
dipeptide), which is a stabilized form of glutamine, and
4mmol glutamine in our culture medium. NH3, besides
being formed from glutamine decomposition, is also formed
in the metabolism of several amino acids and the NH3
decreases by evaporation from the cultivation medium [2,
44].These factors make it challenging to generate an accurate
result about the glutamine metabolism of the cells. However,
we calculated the daily 10% thermal glutamine decay in the
static culture shown in Figure 2.The difference in the slope of
the thermal decay and the curve of glutamine consumption
by the hUC MSCs showed that the cells consumed the
glutamine in the medium and the glutamine decrease cannot
be reduced on the thermal decay.The glutamine consumption
of hUC MSCs needs further investigations and, for this
reason, the supply of the glutamine should be given only by
GlutaMAX to differentiate between glutamine consumption
by the cells and glutamine decay.
With increasing concentrations of lactate and ammonia,
cell growth can be affected by a change of the pH and the
cell toxic properties of these molecules. Schop et al. evaluated
the toxic concentrations of lactate and ammonia for BM
MSCs and found that cell growth decreased at a lactate
concentration of 35.4mmol and an ammonia concentration
of 2.4mM [2]. During the cultivation of the hUC MSCs
in the 12-well plates these concentrations of lactate were
never reached. After ±120 h the toxic levels of ammonia were
exceeded in the 12-well plate, which could cause an increased
cell death. On the other hand, we did not determine the
toxicity of lactate or ammonia in hUC MSCs here, and it has
not been reported in the literature to our knowledge. Due to
the 50%medium exchange in the spinner flask it is likely that
toxic levels of lactate and ammonium were not reached.
Five different hUC MSC isolates (3 female and 2 male)
were expanded in static and dynamic cultivation. In the
present study, no frank differences were observed between
MSCs expanded in static or dynamic culture in differentiation
capacity using the described qualitative differentiation assays.
In contrast, Hupfeld et al. [37], who expanded hUCMSCs in
static culture or dynamic culture using 10% fetal calf serum
enriched medium, reported subtle differences in surface
marker expression (static culture hUC MSCs produced with
positive CD349 staining), gene expression, and cytokine
secretion but did not report difference in differentiation
potential between static and dynamic culture. In contrast,
previous work by Goh et al. [45] and Tseng et al. [46] sug-
gested that cultivation of MSCs on microcarriers may impact
osteogenic differentiation potential, perhaps due to the shear
stress that MSCs grown on microcarriers are subject to.
4.2. Microcarrier Selection and Bead-to-Bead Transfer. Cells
derived from vertebrates have a heterogeneous negative
charge on their surface. Suitable surfaces for the cell adhesion
are dextran, glass, or plastic whose surface can be modified.
During the adhesion process, electrostatic forces and van-
der-Waals forces play an important role in the interaction of
the cell and the growth surface. Divalent cations and glyco-
proteins from themediumare crucial factors for cell adhesion
[47]. These factors show the importance of a suitable growth
surface and have a major influence on cell proliferation. The
higher occupancy of the Pronectin F, Plastic, and Plastic Plus
microcarriers compared to the Glass-coated microcarriers
(Figure 4) leads to the preliminary conclusion that an uneven
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microcarrier surface such as the cross-linked polystyrenes
surface of these microcarriers provides more homogenous
cell distribution and/or better cell attachment. The positive
effect of the hydrogen chloride treatment on the Glass-
coated microcarrier could occur through a modification of
the microcarrier surface. The microcarrier surface may get
charged or rougher (etched) like the modified cross-linked
polystyrene surfaces of the other microcarriers, which could
help the cells to attach. The acid may also remove the glass
surface and exposes the plastic core of themicrocarrier.These
results support the conclusion that hUC MSCs prefer plastic
as substrate for attachment and confirms that the Plastic Plus
microcarriers were a good choice.
The bead-to-bead transfer was based on the assump-
tion of cell detachment from the growth surface and reat-
tachment following cell division. One reason for unsuccess-
ful bead-to-bead transfer could be the ability of the cells
to reattach on the microcarriers in a stirred system, but
the cells showed this ability during the dynamic inoculation
period.With this background the basic assumption of detach-
ment and reattachment could be wrong, which covers the
observation of Hu et al. [48]. For this reason, a homogenous
distribution of the cells during the inoculation period is
of great importance. However, Cierpka et al. [36] showed
a successful bead-to-bead transfer with BM MSCs and
collagen-coatedmicrocarriers (SoloHill), which indicates the
microcarrier as another source of error. We performed the
microcarrier selection with the goal of a high cell yield and
not a good bead-to-bead transfer. Perhaps there is another
microcarrier type that combines both good cell growth and
efficient bead-to-bead transfer and therefore is more suitable
for this kind of hUC MSC expansion process. Presently, we
do not know of such a microcarrier and this needs further
investigation.
4.3. Influence of Donor and Source on Cell Proliferation. In
our study we showed that the gender of the cell donor had no
influence on the cell growth and metabolism.Thementioned
difference in cell proliferation ofMSCs derived from the bone
marrow and umbilical cord [9, 38] could result from the
relative age of the cells.MSCs derived from the umbilical cord
are in fact fetal cells and compared to bone marrow MSCs
which are usually isolated from adults. Also it is generally
thought that stem cells with a low age have longer telomeres
and have the capacity for extended expansion in culture
and reduced senescent [8, 49]. Here, we did not evaluate
whether hUCMSCs grown in dynamic culturemaintain long
telomeres. We previously described the long telomere length
and telomerase expression of statically cultivated hUC MSC
[19]. Flow cytometry determined that dynamically expanded
hUC MSCs did not have different surface marker expression
for the ISCT positive and negative surface marker set (see
Supplemental Figure 1). This finding is in agreement with
previous work by Hupfeld et al. [37] who found similar
surface marker expression for UCMSCs for the ISCTmarker
set but different expression inCD349 (differentially expressed
in statically cultured hUC MSCs and also adipose derived
MSCs, but not those expanded in the bioreactor on micro-
carriers). Colony forming efficiency (CFE) of dynamically
expanded UCMSCs was 4.5–2.5, which falls within the range
observed for hUC MSCs expanded in static culture [17].
This indicates that UC MSCs maintain a high degree of self-
renewal capacity following bioreactor based expansion and
suggests that hUCMSCs remain stemmy or “young.” Finally,
the karyotype of hUC MSCs expanded in dynamic culture
and frozen and thawedwas found to be normal.This indicates
that MSCs subjected to the higher cytoskeletal stress (e.g.,
shear stress) of dynamic culture and freeze/thaw stress were
genetically stable. Therefore, the procedures used for hUC
MSC expansion may be safe for use in cellular therapy.
There is no limit in the age to donate BM MSCs, which
is why the age of the cells from donor to donor can change
strongly with range of many years. In addition, the bone
marrow contents change over the lifespan. The red marrow
space changes to a yellow marrow by fat deposition, which
complicates the extraction [8]. Another aspect on the quality
of the isolated cells could be the donor and the donor’s
physical health. The kind of lifestyle (healthy, unhealthy) or
if the donor has/had any diseases could affect the condition
on the cells. These aspects may have more impact on the cell
proliferation and expansion than the gender of the donor.
5. Conclusion
We identified the relevant process parameters for a micro-
carrier-based expansion of hUC MSCs. To prevent micro-
carrier agglomeration a dynamic inoculation strategy and an
increase of the agitation over the culture time are required.
A microcarrier concentration of 25 g⋅L−1 and a seeding den-
sity of 8000 cells⋅cm−2 were suitable. The Plastic Plus micro-
carriers were suitable for the expansion of the hUCMSCs, but
not for the bead-to-bead transfer.
A known problem of microcarrier-based expansion is
the cell number determination. For this reason an online
monitoring system like dielectric spectroscopy should be
chosen for the expansion of hUC MSCs in a large-scale
stirred tank bioreactor. The bead-to-bead transfer for hUC
MSC expansion process should be investigated with other
microcarrier types. For further experiments, a medium opti-
mization towards a high glucose medium should be carried
out to prevent a medium exchange. Another possibility is
to establish a controlled and monitored glucose feed, with
regard to the fact that the cell growth does not get affected
by toxic levels of lactate and ammonium.
In the static and dynamic cultures of hUC MSCs, we
found no difference in cell growth and metabolism between
cells from male and female donors. On one hand this
indicates a successful process transfer from static to dynamic
system and on the other hand the age and source of the cells
have more influence than the gender. In fact MSCs derived
from umbilical cord are very young with a high proliferation
activity and the advantages of cell isolation make these cells a
good alternative to MSCs derived from bone marrow.
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